Abstract: Acute kidney injury （AKI） is a diverse group of renal diseases characterized by a dramatic decline in renal function. Not only AKI has a high mortality rate, but also poor renal adaptation or incomplete repair after acute phase may also lead to renal fibrosis and eventually to chronic kidney disease （CKD）. Currently there are no effective measures for limiting damage, promoting recovery and improving survival. Proteolysis targeting chimeras （PROTACs） provide a novel strategy for AKI drug development through ubiquitin-proteasome system of degrading target proteins. This review summarized promising therapeutic targets for AKI and the application of PROTACs technology.